A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Solid Tumors

ALLIANCE A031701: A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE

Durvalumab with Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)

ALLIANCE A031501: PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION

A Phase II Trial of the PD-1 Antibody Nivolumab in Combination with Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

A231601CD:   Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-surgical Toolkit (OPTI-SURG)

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

EA9161, “A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive

A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma